In addition, oncogenic KRAS mutations are commonly seen in most human pancreatic tumors [57] and are associated with increased glucose and glutamate consumption to support anabolic processes, including nucleotide, lipid and nonessential amino acid biosynthesis [58]. The gene discussed is KRAS; the disease is pancreatic neoplasm.